Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 924 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Psoriasis Clear all
Completed Phase 3 Interventional

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis

NCT03331523
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
Calcipotriene/Betamethasone Dipropionate, Taclonex®, Placebo
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
18 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
31
States / cities
Encinitas, California • Fremont, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2018 · Synced Oct 24, 2026, 5:38 PM EDT
Completed Phase 4 Interventional

Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis

NCT00493324
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
alefacept, polyvalent pneumococcal vaccine
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
5
States / cities
Birmingham, Alabama • San Diego, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 24, 2026, 5:38 PM EDT
Completed Early Phase 1 Interventional

An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Deucravacitinib for the Treatment of Nail Psoriasis

NCT05124080
View directory record Official record
Conditions
Nail Psoriasis
Interventions
Deucravacitinib
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 24, 2026, 5:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study to Evaluate Vectical in Combination With Clobex Spray to Treatment Plaque Psoriasis

NCT01205880
View directory record Official record
Conditions
Psoriasis
Interventions
Calcitriol ointment, Clobetasol spray
Drug
Lead sponsor
Emer, Jason, M.D.
Individual
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2010 · Synced Oct 24, 2026, 5:38 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis

NCT00954915
View directory record Official record
Conditions
Psoriasis
Interventions
teplizumab
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Ann Arbor, Michigan • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Oct 24, 2026, 5:38 PM EDT
Completed Phase 3 Interventional

Investigator Initiated Trial to Study Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults

NCT05203315
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Duobrii 0.01 % / 0.045 % Topical Lotion, CeraVe, Topical Cream
Drug
Lead sponsor
Austin Institute for Clinical Research
Network
Eligibility
18 Years to 99 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Houston, Texas • Pflugerville, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 24, 2026, 5:38 PM EDT
Terminated Phase 1 Interventional

Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease

NCT03656627
View directory record Official record
Conditions
Autoimmune Diseases, Non-small Cell Lung Cancer, Rheumatoid Arthritis, Psoriasis, Giant Cell Arteritis, Polymyalgia Rheumatica, Systemic Lupus Erythematosus, Crohn Disease, Multiple Sclerosis, Ulcerative Colitis
Interventions
Nivolumab
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Chicago, Illinois • Boston, Massachusetts • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 24, 2026, 5:38 PM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III)

NCT07426120
View directory record Official record
Conditions
Psoriasis Vulgaris, Topical Administration, Phase III
Interventions
Total coumarin (TC) cream, Vehicle cream
Drug
Lead sponsor
Psoriasis Research Institute of Guangzhou
Industry
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 24, 2026, 5:38 PM EDT
Completed No phase listed Observational

Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation

NCT02330380
View directory record Official record
Conditions
Psoriasis, Inflammation
Interventions
Methotrexate, Ustekinumab, Etanercept, Adalimumab, Acitretin, UVB Excimer Laser, Narrowband UVB
Drug · Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 24, 2026, 5:38 PM EDT
Completed Phase 1 Interventional

Bioavailability in Patient With Psoriasis: Metoject Prefilled Pen

NCT02097173
View directory record Official record
Conditions
Psoriasis
Interventions
Methotrexate
Drug
Lead sponsor
medac GmbH
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 24, 2026, 5:38 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Effect of Chronic Inflammation on Myocardial Perfusion and Function

NCT04870827
View directory record Official record
Conditions
Psoriasis
Interventions
13N Amonia
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Oct 24, 2026, 5:38 PM EDT
Completed Phase 3 Interventional

A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00570986
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Placebo, ABT-874
Drug · Biological
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
1,465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
93
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 24, 2026, 5:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Brain Changes in Psoriasis After Secukinumab Treatment

NCT04717466
View directory record Official record
Conditions
Psoriasis, Healthy
Interventions
Secukinumab
Biological
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 24, 2026, 5:38 PM EDT
Completed Phase 3 Interventional Results available

Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy

NCT00566722
View directory record Official record
Conditions
Psoriasis
Interventions
adalimumab
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
18
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2011 · Synced Oct 24, 2026, 5:38 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Metabolic Profiling of Immune Responses in Immune-mediated Diseases

NCT04864886
View directory record Official record
Conditions
Primary Immunodeficiency, Psoriasis, Atopic Dermatitis, Immune-mediated Diseases
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 24, 2026, 5:38 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Efficacy of Etanercept Treatment in Adults Who Failed Therapy With Apremilast

NCT02749370
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Etanercept
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
22
States / cities
Scottsdale, Arizona • Beverly Hills, California • Fountain Valley, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 24, 2026, 5:38 PM EDT
Completed Phase 4 Interventional

Combination of Sotyktu and Enstilar for Plaque Psoriasis

NCT06329258
View directory record Official record
Conditions
Psoriasis
Interventions
Enstilar, Deucravacitinib
Drug
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Oct 24, 2026, 5:38 PM EDT
Completed Not applicable Interventional Results available

Use of Localized NB-UVB (Levia®) in the Treatment of Plaque-psoriasis

NCT02107482
View directory record Official record
Conditions
Psoriasis
Interventions
Levia Narrow Band UVB, Levia sham/visible-light source
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 24, 2026, 5:38 PM EDT
Completed Phase 1 Interventional Results available

Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects

NCT01937260
View directory record Official record
Conditions
Psoriasis
Interventions
Brodalumab
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Anaheim, California • Irvine, California • Ocala, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 24, 2026, 5:38 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of IDP-122 in Participants With Plaque Psoriasis

NCT02515097
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
IDP-122 Lotion, IDP-122 Vehicle Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
15
States / cities
Santa Ana, California • Boynton Beach, Florida • Clearwater, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 24, 2026, 5:38 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis

NCT01090310
View directory record Official record
Conditions
Non-infectious Uveitis
Interventions
AIN457, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
10
States / cities
Beverly Hills, California • Atlanta, Georgia • Louisville, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 24, 2026, 5:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Activating the Cholinergic Anti-Inflammatory Pathway in Healthy Volunteers and People With Inflammatory Arthritis

NCT06555562
View directory record Official record
Conditions
Psoriatic Arthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
Interventions
Ultrasound Stimulation, Non-active ultrasound stimulation
Device
Lead sponsor
Surf Therapeutics
Industry
Eligibility
22 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Austin, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 24, 2026, 5:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Immunological Basis for Treatment Resistance to Anti-TNF Treatments

NCT01971346
View directory record Official record
Conditions
Psoriasis
Interventions
etanercept
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 24, 2026, 5:38 PM EDT
Completed Phase 3 Interventional

A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001

NCT06588738
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Envudeucitinib, Placebo, Apremilast
Drug
Lead sponsor
Alumis Inc
Industry
Eligibility
18 Years and older
Enrollment
862 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
43
States / cities
Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 24, 2026, 5:38 PM EDT